Akademik Veri Yönetim Sistemi
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, cilt.221, 2022 (SCI-Expanded)
Schizophrenia is a chronic disabling disease affecting 1 % of the population. Current antipsychotics have limited efficacy in mitigating the severity of the symptoms of the disease. Therefore, searching for new therapeutic targets is essential. Previous studies have shown that alpha 2C-adrenoceptor antagonists may have antipsychotic and pro-cognitive effects. Therefore, the current study evaluates the behavioral and neurochemical effects of JP -1302, a selective alpha 2C-adrenoceptor antagonist, in a model of schizophrenia-like deficits induced by sub -chronic ketamine (KET) administration.Here, we administered ketamine (25 mg/kg, i.p.) to male and female Wistar rats for eight consecutive days. On the last two days of ketamine administration, rats were pretreated with either JP-1302 (1-3-10 mu mol/kg, i.p.), chlorpromazine (0.1 mg/kg, i.p.), or saline, and the behavioral tests were performed. Behaviors related to positive (locomotor activity), negative (social interaction), and cognitive (novel object recognition) symptoms of schizophrenia were assessed. Glutamate, glutamine, GABA levels, and alpha 2C-adrenoceptor expression were measured in the frontal cortex and the hippocampus. Tyrosine hydroxylase immunocytochemical reactivity was also shown in the midbrain regions.Sub-chronic ketamine administration increased locomotor activity and produced robust social interaction and object recognition deficits, and JP-1302 significantly ameliorated ketamine-induced cognitive deficits. Ketamine induced a hyperdopaminergic activity in the striatum, which was reversed by the treatment with JP-1302. Also, the alpha 2C-adrenoceptor expression was higher in the frontal cortex and hippocampus in the ketamine-treated rats.Our findings confirm that alpha 2C-adrenoceptor antagonism may be a potential drug target for treating cognitive disorders related to schizophrenia.